As the human HLA-D genetic region is structurally analogous to the murine H2-I region, it should also control human immune responses using T-lymphocyte clones which recognize cell-surface antigens encoded by the D-region and influenza virus-specific clones which express antigen-specific help and are restricted to D-region interaction products. The genetic restriction of helper clones will be identified in panel studies using HLA phenotyped, histocompatible and histoincompatible antigen presenting cells in population and family studies. Restriction specificities will be further correlated with subregions of HLA-D as detected by exquisitely specific alloreactive T.Cs defining new D-region epitopes and gene products. The ability of cones to mediate help will be assayed using an ELISA to detect induction of in vitro production of specific antibodies to influenza virus. Murine monoclonal antibodies directed against human Class II antigens will also be used to block presentation in analyses to identify functionally important interaction molecules. With the above approaches it should be possible to begin to identify the specific genetic regions which control human immune responsiveness. If the clinical manipulation of immunity is ever to be realized in humans, then it must be grounded in a firm structural and functional understanding of the human HLA-D region. Through the use of functional, antigen-specific T-cell clones it should be possible to elucidate how human immune networks operate. The proposed studies are, therefore, prerequisition steps toward the clinical use of immunomodulatory therapy.

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Research Project (R01)
Project #
7R01AI022832-01
Application #
3134396
Study Section
Immunobiology Study Section (IMB)
Project Start
1985-04-01
Project End
1986-03-31
Budget Start
1985-04-01
Budget End
1986-03-31
Support Year
1
Fiscal Year
1985
Total Cost
Indirect Cost
Name
Bloodcenter of Wisconsin, Inc.
Department
Type
DUNS #
City
Milwaukee
State
WI
Country
United States
Zip Code
53233
Brady, M S; Lee, F; Eckels, D D et al. (2000) Restoration of alloreactivity of melanoma by transduction with B7.1. J Immunother 23:353-61
Brady, M S; Lee, F; Petrie, H et al. (2000) CD4(+) T cells kill HLA-class-II-antigen-positive melanoma cells presenting peptide in vitro. Cancer Immunol Immunother 48:621-6
Brady, M S; Eckels, D D; Lee, F et al. (1999) Cytokine production by CD4+ T-cells responding to antigen presentation by melanoma cells. Melanoma Res 9:173-80
Brady, M S; Eckels, D D; Ree, S Y et al. (1996) MHC class II-mediated antigen presentation by melanoma cells. J Immunother Emphasis Tumor Immunol 19:387-97
Ota, M; Geiger, M J; Rosen-Bronson, S et al. (1996) Diverse usage of human T-cell receptor gene segments in HLA-DR1 allospecific T-cell clones. Hum Immunol 49:122-9
Wu, S; Gorski, J; Eckels, D D et al. (1996) T cell recognition of MHC class II-associated peptides is independent of peptide affinity for MHC and sodium dodecyl sulfate stability of the peptide/MHC complex. Effects of conservative amino acid substitutions at anchor position 1 of influenza matrix pr J Immunol 156:3815-20
Kawaguchi, M; Eckels, D D (1995) Differential activation through the TCR-CD3 complex affects the requirement for costimulation of human T cells. Hum Immunol 43:136-48
Garlie, N K; Eckels, D D (1994) Idiotype-specific autologous T-cell interactions restricted by HLA-DR. Hum Immunol 39:69-75
Geiger, M J; Bull, M; Eckels, D D et al. (1993) Amplification of complementary DNA from mRNA with unknown 5' ends by one-way polymerase chain reaction. Methods Enzymol 218:321-35
Hurley, C K; Steiner, N; Wagner, A et al. (1993) Nonrandom T cell receptor usage in the allorecognition of HLA-DR1 microvariation. J Immunol 150:1314-24

Showing the most recent 10 out of 26 publications